Table 2 Treatment and outcomes
Imatinib response/dose/treatment duration | Imatinib PFS and TTP | Sunitinib response/dose/treatment duration/BSA | Sunitinib PFS and TTP | Overall follow up | Outcome | Adverse event/Toxicity during sunitinib treatment | |
|---|---|---|---|---|---|---|---|
Patient A | SD then PD; 400 mg OD then 300 mg OD; 8mo | PFS 17mo TTP 17mo | SD liver metastasis; 50 mg OD 4/2 schedule, then 37.5 mg OD; 73mo; 1.52m2 | PFS 73mo TTP No progression | 163mo | AWD on sunitinib since 2008 | Hand and foot syndrome /TG 1 Arterial hypertension/TG 1 Skin rash/TG 2 Anaemia/TG 2 Diarrhoea/TG 2 Hypothyroidism/TG 2 |
Patient B | SD then PD; 400 mg OD; 9mo | PFS 8mo TTP 8mo | SD then PD; 37.5 mg OD then 50 mg OD 4/2 schedule; 7mo; 1.39m2 | PFS 6mo TTP 6mo | 159mo | AWD on regorafenib | Hypothyroidism/ TG 1 Diarrhoea/ TG 2 Skin rash/ TG 1 |
Patient C | SD then PD; 400 mg OD then 200 mg OD; 9mo | PFS 8mo TTP 8mo | SD then PD; 25 mg OD then 37.5 mg OD then 25 mg OD; 23 months; 1.28m2 | PFS 6mo TTP 6mo | 88mo | AWD on imatinib/doxorubicin | Cholecystitis /TG 3 Diarrhoea/TG 1 |
Patient D | PD; 400 mg OD; 12mo | PFS 12mo TTP 12mo | SD then PD; 50 mg OD 4/2 schedule then 37.5 mg OD; 24mo; 1.39m2 | PFS 23mo TTP 23mo | 260mo | AWD on treatment (nilotinib, then imatinib + doxorubicin, then imatinib 800 mg OD | Hypothyroidism/TG 3 Pyrosis/TG 1 Anaemia/TG 3 Thrombocytopenia/TG 2 Fatigue/TG 2 Amenorrhoea/TG 2 Discoloration of skin and hair/TG 2 Hand and foot syndrome/TG 2 |
Patient E | SD; 400 mg BID then 200 mg OD then 300 mg OD; 7mo | PFS 7mo TTP NA – intolerance (neutropenia, fatigue, joint pain) | PD; 25 mg OD 4/2 schedule (reduced due to prior intolerance of imatinib); 5mo; 1.51m2 | PFS 5mo TTP 5mo | 139mo | AWD, PD on nilotinib after sunitinib. Slow PD- asymptomatic, no treatment since 2011 | Abdominal pain/TG 2 Bone pain/TG 2 Fatigue/TG 2 Patient elected to discontinue sunitinib due to above side effects, PD then documented |
Patient F | NA | NA | PD; 50 mg OD 4/2 schedule; 1mo; 1.50m2 | PFS 1mo TTP 1mo | 25mo | DOD, after sunitinib also failed trametinib, regorafenib, a phase 1 clinical trial and pazopanib | Fatigue/TG 1 Thrombocytopenia/TG 1 |
Patient G | SD then PD; 400 mg OD; 14mo | PFS 14mo TTP 14mo | SD then PD; 37.5 mg OD then discontinued for 3mo for toxicity then restarted 12.5 mg OD increasing to 25 mg OD; 17mo; 1.65m2 | PFS 17mo TTP 17mo | 76mo | AWD, no treatment since sunitinib and subsequent SD under observation from 2012 | Fatigue/TG 1 Oedema/TG 2 Epistaxis/TG 1 Headaches/TG 1 |
Patient H | SD then PD; 400 mg OD then 800 mg OD: 49mo | PFS 9mo TTP 9mo | SD for duration but initial minor response; Initial dose 50 mg OD, lowest dose 12.5 mg OD; 17mo; 1.60m2 | PFS 5mo TTP 5mo | 173mo | AWD on imatinib | Fatigue/TG 3 Mucositis/TG 3 Diarrhoea/TG 3 |
Patient I | SD then PD; 400 mg OD; 1mo | PFS 2mo TTP 2mo | SD then PD then SDa; 50 mg OD then 37.5 mg OD; >42mo (RFA during treatment for liver metastases); b1.68m2 | PFS 28mo TTP 28mo | 86mo | AWD on sunitinib | Mucositis /TG 2 Diarrhoea/TG 2 Hypertension/TG 2 |